利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

868 条记录 (耗时 0.032 秒)

    NOROVIRUS ANTIBODIES
    2.
    发明申请
    NOROVIRUS ANTIBODIES 审中-公开

    公开(公告)号：WO2019057755A1

    公开(公告)日：2019-03-28

    申请号：PCT/EP2018/075324

    申请日：2018-09-19

    申请人： UNIVERSITÄT HEIDELBERG ,  DEUTSCHES KREBSFORSCHUNGSZENTRUM

    发明人： HANSMAN, Grant ,  KOROMYSLOVA, Anna

    IPC分类号： C07K16/10

    CPC分类号： C07K16/10 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2317/92 ,  C12N2770/16011 ,  C12N2770/16023

    摘要： The present invention relates to a binding polypeptide specifically binding to an epitope comprised in an amino acid sequence corresponding to amino acids 250 to 300 of the norovirus genotype II.10 capsid polypeptide., and to a polynucleotide encoding the same. The present invention further relates to a composition comprising the binding polypeptide according to the present invention and a carrier, and to the binding polypeptide or the composition comprising the same use in diagnosis and/or for use in medicine. Further more, the present invention relates to kits, devices, vaccines, methods, and uses related to the binding polypeptide of the present invention.

    VARIABLE NEW ANTIGEN RECEPTOR (VNAR) ANTIBODIES AND ANTIBODY CONJUGATES TARGETING TUMOR AND VIRAL ANTIGENS
    5.
    发明申请
    VARIABLE NEW ANTIGEN RECEPTOR (VNAR) ANTIBODIES AND ANTIBODY CONJUGATES TARGETING TUMOR AND VIRAL ANTIGENS 审中-公开
    靶向肿瘤和病毒抗原的可变新型抗原受体（VNAR）抗体和抗体偶联物

    公开(公告)号：WO2017196847A1

    公开(公告)日：2017-11-16

    申请号：PCT/US2017/031758

    申请日：2017-05-09

    申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  UNIVERSITY OF MARYLAND, BALTIMORE

    发明人： HO, Mitchell ,  FENG, Mingqian ,  FLAJNIK, Martin, F.

    IPC分类号： C07K16/10 ,  C07K16/28 ,  C07K16/32

    CPC分类号： C07K16/28 ,  C07K16/10 ,  C07K16/2896 ,  C07K16/32 ,  C07K2317/20 ,  C07K2317/33 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： The antigen binding region of immunoglobulin new antigen receptor (IgNAR) antibodies found in cartilaginous fish is composed solely of a heavy chain, which makes it one of the smallest immunoglobulins in the animal kingdom. The reduced size allows the variable region (V NAR domain) of this immunoglobulin to bind poorly exposed epitopes in target proteins. Construction of a naive phage-displayed V NAR antibody library from six adult nurse sharks is described. Isolation and characterization of a panel of binders from the V NAR library is also described. The V NAR antibodies bind a variety of tumor antigens, including glypican-3 (GPC3), HER2 and PDl, and viral antigens, including the spike protein of Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus.

    摘要翻译： 在软骨鱼中发现的免疫球蛋白新抗原受体（IgNAR）抗体的抗原结合区仅由重链组成，这使得它成为动物界最小的免疫球蛋白之一。 减小的尺寸允许该免疫球蛋白的可变区（V NAR结构域）结合目标蛋白中暴露不足的表位。 描述了从六名成年护士鲨鱼构建天然噬菌体展示V NAR抗体文库。 还描述了来自VN NAR文库的一组结合物的分离和表征。 V NAR抗体结合多种肿瘤抗原，包括磷脂酰肌醇蛋白聚糖-3（GPC3），HER2和PD1以及病毒抗原，包括中东呼吸综合征（MERS）病毒的刺突蛋白和严重急性 呼吸综合征（SARS）病毒。

    ANTI-ANTITHROMBIN SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF
    6.
    发明申请
    ANTI-ANTITHROMBIN SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF 审中-公开
    抗反应性单克隆抗体及其含有多肽的抗体

    公开(公告)号：WO2017158176A1

    公开(公告)日：2017-09-21

    申请号：PCT/EP2017/056424

    申请日：2017-03-17

    申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS-SUD

    发明人： LENTING, Peter ,  DENIS, Cécile ,  CHRISTOPHE, Olivier ,  AYME, Gabriel

    IPC分类号： C07K16/38 ,  A61K39/00

    CPC分类号： C07K16/36 ,  A61K38/1725 ,  A61K2039/505 ,  A61K2039/507 ,  A61P7/04 ,  C07K14/472 ,  C07K16/38 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31 ,  C12N15/62

    摘要： The present invention relates to isolated single-domain antibodies (sdAb) directed against Antithrombin (AT) to prolong the half-life of the proteins. Inventors have generated isolated single domain antibodies (sdAbs) directed against antithrombin. They observed that in amidolytic assays, sdAbs are incapable of blocking the inhibitory antithrombin activity towards thrombin and factor Xa in the presence of heparin. The different combinations of sdAb were able to block the inhibitory antithrombin activity towards thrombin and factor Xa in mice. Thus, the inventors propose to use different combinations of sdAb to block the inhibitory function of antithrombin in order to promote thrombin generation and thus treat haemophilia and other conditions that are associated with bleeding. Accordingly, the invention relates also to a method of preventing or treating bleeding disorders in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of the single domain antibodies or the drug conjugate of the invention.

    摘要翻译： 本发明涉及针对抗凝血酶（AT）以延长蛋白质半衰期的分离的单域抗体（sdAb）。 发明人已经产生针对抗凝血酶的分离的单域抗体（sdAb）。 他们观察到，在酰胺分解测定中，sdAb在肝素存在下不能阻断对凝血酶和因子Xa的抑制性抗凝血酶活性。 sdAb的不同组合能够阻断小鼠中对凝血酶和因子Xa的抑制性抗凝血酶活性。 因此，发明人建议使用不同的sdAb组合来阻断抗凝血酶的抑制功能，以促进凝血酶的产生，从而治疗与出血有关的血友病和其他病症。 因此，本发明还涉及预防或治疗有需要的受试者的出血性疾病的方法，其包括向所述受试者施用治疗有效量的本发明的单域抗体或药物缀合物。